Published in J Virol on January 01, 1993
The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J Virol (1996) 1.93
Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans. J Virol (2008) 1.64
Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion. J Virol (2004) 1.43
Intracellular processing of human herpesvirus 6 glycoproteins Q1 and Q2 into tetrameric complexes expressed on the viral envelope. J Virol (2004) 1.20
Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H. J Virol (1995) 1.02
HCMV gB shares structural and functional properties with gB proteins from other herpesviruses. Virology (2012) 1.01
Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog (2014) 0.97
Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies. PLoS Pathog (2012) 0.89
Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies. Clin Vaccine Immunol (2013) 0.89
Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. Hum Vaccin Immunother (2012) 0.84
Human Cytomegalovirus gH/gL Forms a Stable Complex with the Fusion Protein gB in Virions. PLoS Pathog (2016) 0.77
Importance of highly conserved peptide sites of HCMV gO for the formation of the gH/gL/gO complex. J Virol (2016) 0.76
Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein. Nat Commun (2016) 0.75
Human cytomegalovirus gH stability and trafficking are regulated by ER-associated degradation and transmembrane architecture. Sci Rep (2016) 0.75
Synthetic DNA approach to cytomegalovirus vaccine/immune therapy. Adv Exp Med Biol (2015) 0.75
Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex. J Virol Methods (2017) 0.75
Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol (1987) 6.42
Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med (1982) 5.72
Conformations of immunoglobulin hypervariable regions. Nature (1990) 5.31
The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med (1992) 5.11
Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. J Mol Biol (1986) 4.16
Three-dimensional structure of an antibody-antigen complex. Proc Natl Acad Sci U S A (1987) 3.48
Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr (1981) 3.42
Serologic differentiation of viruses responsible for cytomegalic inclusion disease. Virology (1960) 3.36
Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex. Proc Natl Acad Sci U S A (1989) 2.65
A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods (1989) 2.53
Protein folding by restrained energy minimization and molecular dynamics. J Mol Biol (1983) 2.51
Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci U S A (1984) 2.32
Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology (1988) 2.14
The galactan-binding immunoglobulin Fab J539: an X-ray diffraction study at 2.6-A resolution. Proteins (1986) 1.96
The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86. Virology (1989) 1.49
Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med (1987) 1.48
The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J Virol (1992) 1.47
Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol (1989) 1.38
Three-dimensional structure of a fluorescein-Fab complex crystallized in 2-methyl-2,4-pentanediol. Proteins (1989) 1.31
Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J Virol (1991) 1.28
Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis (1991) 1.20
Antigenic and functional organization of human parainfluenza virus type 3 fusion glycoprotein. J Virol (1989) 1.06
Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children. J Virol (1984) 1.02
Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol (1992) 0.99
Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies. Virology (1988) 0.99
A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein. J Gen Virol (1989) 0.96
Probing antibody diversity by 2D NMR: comparison of amino acid sequences, predicted structures, and observed antibody-antigen interactions in complexes of two antipeptide antibodies. Biochemistry (1989) 0.90
Human immune responses to major human cytomegalovirus glycoprotein complexes. J Virol (1988) 0.88
Complement-independent neutralising monoclonal antibody with differential reactivity for strains of human cytomegalovirus. J Med Virol (1989) 0.87
NMR-derived model for a peptide-antibody complex. Biochemistry (1990) 0.87
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res (2001) 76.97
Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell (1993) 10.36
A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Genes Dev (1998) 6.74
The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med (1992) 5.11
The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem (2001) 4.74
Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med (2001) 3.90
Genetic influences on osteoarthritis in women: a twin study. BMJ (1996) 3.70
Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA (1986) 3.37
A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol (1990) 3.00
Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr (1997) 2.93
Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology (1984) 2.91
Integrin alpha 6/beta 4 complex is located in hemidesmosomes, suggesting a major role in epidermal cell-basement membrane adhesion. J Cell Biol (1991) 2.88
A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods (1989) 2.53
Mechanotransduction in response to shear stress. Roles of receptor tyrosine kinases, integrins, and Shc. J Biol Chem (1999) 2.51
Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J (1992) 2.40
Response of the pulmonary vasculature to hypoxia and H+ ion concentration changes. J Clin Invest (1966) 2.38
Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol (2000) 2.36
Selective decontamination of the digestive tract reduces gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation. Crit Care Med (1994) 2.21
Delta-like and gtl2 are reciprocally expressed, differentially methylated linked imprinted genes on mouse chromosome 12. Curr Biol (2000) 2.19
Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol (1991) 2.16
Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16
Use of gelatin/plasma coated flasks for isolating human peripheral blood monocytes. J Immunol Methods (1983) 2.12
Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat Commun (2013) 2.10
Therapeutic hypercapnia reduces pulmonary and systemic injury following in vivo lung reperfusion. Am J Respir Crit Care Med (2000) 2.05
Congenital and perinatal cytomegalovirus infections. Rev Infect Dis (1990) 2.04
The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. J Bone Miner Res (1996) 1.99
Distinct binding sites for zinc and double-stranded RNA in the reovirus outer capsid protein sigma 3. Mol Cell Biol (1988) 1.96
Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics (1999) 1.96
Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res (1996) 1.95
Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med (2001) 1.95
Human cytomegalovirus pp28 (UL99) localizes to a cytoplasmic compartment which overlaps the endoplasmic reticulum-golgi-intermediate compartment. J Virol (2000) 1.93
Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1. J Biol Chem (2000) 1.91
Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract (1995) 1.88
Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus. J Virol (1986) 1.85
DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol Genomics (2001) 1.85
Molecular mechanism of endothelial growth arrest by laminar shear stress. Proc Natl Acad Sci U S A (2000) 1.83
Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol (1990) 1.83
Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins. J Infect Dis (1989) 1.82
Sustained endotoxemia leads to marked down-regulation of early steps in the insulin-signaling cascade. Crit Care Med (2001) 1.78
Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation (2001) 1.78
Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex. J Virol (1997) 1.73
Isolation and biochemical characterization of the mammalian reovirus type 3 cell-surface receptor. Proc Natl Acad Sci U S A (1985) 1.70
Choosing the best method for radiological assessment of patellofemoral osteoarthritis. Ann Rheum Dis (1996) 1.66
Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med (1987) 1.66
Detection of cytomegalovirus antibody with latex agglutination. J Clin Microbiol (1985) 1.66
Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance. Am J Transplant (2014) 1.63
Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus. Virus Res (1985) 1.63
Association of pain with radiological changes in different compartments and views of the knee joint. Osteoarthritis Cartilage (1996) 1.61
Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol (2010) 1.58
Identification of a new fibroblast growth factor receptor, FGFR5. Gene (2001) 1.54
Fibronectin alters the phenotypic properties of cultured chick embryo chondroblasts. Cell (1979) 1.53
The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception (1999) 1.50
Stabilization and localization of Xist RNA are controlled by separate mechanisms and are not sufficient for X inactivation. J Cell Biol (1998) 1.49
The molecular defects of alpha-thalassemia in the Filipino. Hemoglobin (1977) 1.47
Shear stress activates p60src-Ras-MAPK signaling pathways in vascular endothelial cells. Arterioscler Thromb Vasc Biol (1998) 1.46
Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc Natl Acad Sci U S A (1986) 1.43
Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis (1995) 1.42
Outpatient intensive chemotherapy for small cell lung cancer: five years experience of modified 'ICE' ifosfamide carboplatin and etoposide. Clin Oncol (R Coll Radiol) (2002) 1.41
Characterization of the calmodulin binding domain of neuromodulin. Functional significance of serine 41 and phenylalanine 42. J Biol Chem (1991) 1.41
Small cell lung cancer treated in southeast Wales. Clin Oncol (R Coll Radiol) (2006) 1.40
Action of molecular switches in GPCRs--theoretical and experimental studies. Curr Med Chem (2012) 1.40
Prevalence of diabetes mellitus and impaired glucose tolerance in a New Zealand multiracial workforce. N Z Med J (1991) 1.39
Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol (1983) 1.38
Cohort reconstruction: which infants can be restudied at school age? Paediatr Perinat Epidemiol (1991) 1.38
Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus détente. Immunity (2001) 1.37
Human cytomegalovirus (HCMV) smallest capsid protein identified as product of short open reading frame located between HCMV UL48 and UL49. J Virol (1996) 1.35
Mouse-protective properties of Bordetella pertussis serotypes in passive tests. J Bacteriol (1967) 1.34
Structural similarities between the mammalian beta-adrenergic and reovirus type 3 receptors. Proc Natl Acad Sci U S A (1985) 1.34
Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J Virol (1998) 1.34
Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics (1997) 1.33
Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol (1990) 1.33
The interaction of link proteins with proteoglycan monomers in the absence of hyaluronic acid. Biochem Biophys Res Commun (1978) 1.33
Organosolv pretreatment for enzymatic hydrolysis of poplars: I. Enzyme hydrolysis of cellulosic residues. Biotechnol Bioeng (1988) 1.33
PM2.5 chemical source profiles for vehicle exhaust, vegetative burning, geological material, and coal burning in Northwestern Colorado during 1995. Chemosphere (2001) 1.31
Early clinical manifestations and intellectual outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr (1987) 1.30
Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics (1995) 1.29
Bordetella pertussis serotypes in the United States. Appl Microbiol (1969) 1.29
Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation. Surgery (1988) 1.29
H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28
Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J Virol (1991) 1.28
Influences of competition level, gender, player nationality, career stage and playing position on relative age effects. Scand J Med Sci Sports (2008) 1.27
Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status, and ion transporter gene expression. Am J Physiol Gastrointest Liver Physiol (2011) 1.27
Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology (1996) 1.27
Spontaneous remodeling of the peripheral retinal vasculature in sickling disorders. Am J Ophthalmol (1975) 1.26
Experimentally induced degenerative joint lesions following partial meniscectomy in the rabbit. Arthritis Rheum (1973) 1.25
Colonic perforation following mild trauma in a patient with Crohn's disease. Am J Emerg Med (1990) 1.25
A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol (1986) 1.25
The effects of continuous blood gas monitoring during cardiopulmonary bypass: a prospective, randomized study--Part I. J Extra Corpor Technol (2000) 1.24
The purification and cyanogen bromide cleavage of the 'link proteins' from cartilage proteoglycan. Biochem Biophys Res Commun (1977) 1.24
Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013. Euro Surveill (2013) 1.24
Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis (1997) 1.24
Mechanism of decreased in vitro murine macrophage cytokine release after exposure to carbon dioxide: relevance to laparoscopic surgery. Ann Surg (1997) 1.24
Maturational changes in renal blood flow in piglets. Pediatr Res (1970) 1.24
Evidence of infection with organisms producing Shiga-like toxins in household contacts of children with the hemolytic uremic syndrome. Pediatr Infect Dis J (1991) 1.23
Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. J Virol (1999) 1.23
Impact of in situ chemical oxidation on contaminant mass discharge: linking source-zone and plume-scale characterizations of remediation performance. Environ Sci Technol (2011) 1.21
Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol (1996) 1.20
Structural and immunological characterization of the intracellular forms of an abundant 68,000 Mr human cytomegalovirus protein. J Gen Virol (1987) 1.20